Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Opening Session Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Nov

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Opening Session Panel Discussion

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

16 Million PRISM Trial Will Explore AI in Breast Cancer Screening

Axicabtagene Ciloleucel in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives

Diminishing the National Cancer Institute Threatens Americans

Zanzalintinib Plus Atezolizumab vs Regorafenib in Previously Treated Metastatic Colorectal Cancer Without MSI-H or dMMR Tumors